Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2019 | MRD evaluation by MFC and NGS for MM

Francesca Gay • 7 Dec 2019
ASH 2019
Multiple Myeloma
FORTE

Speaking from the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL, Francesca Gay, MD, PhD, University of Turin, Turin, Italy, discusses the analysis and comparison of MRD data from the FORTE trial (NCT02203643) by multiparameter flow cytometry (MFC) and next generation sequencing (NGS). MRD assessment both by MFC and NGS showed a good concordance.

More from Francesca Gay

An insight into designing randomized studies in high-risk myeloma
Binod Dhakal et al. • 4 Nov 2024
FORTE: MRD by MFC or NGS in myeloma 1:46
FORTE: MRD by MFC or NGS in myeloma
Francesca Gay • 14 Dec 2020
MRD: Paving the way for future clinical trials in myeloma 1:30
MRD: Paving the way for future clinical trials in myeloma
Francesca Gay • 14 Dec 2020
FORTE: KRd versus KCd treatment for myeloma 0:45
FORTE: KRd versus KCd treatment for myeloma
Francesca Gay • 14 Dec 2020

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals